On 22 April 2026, we were pleased to welcome the Mayor of Sant Joan Despí, Ms. Belén García, to Neuraxpharm’s manufacturing, R&D, and corporate facilities at our Spanish headquarters. The visit from the Mayor, who was accompanied by delegates from the City Council, formed part of an institutional engagement to highlight Neuraxpharm’s continued commitment to patients and innovation along with the role of the pharmaceutical industry in the Barcelona metropolitan area.
The morning began with a company presentation centred on Neuraxpharm’s values and vision, followed by a tour of Neuraxpharm’s production plant and HealthTech R&D centre. Discussions focused on Neuraxpharm’s operations, scientific capabilities and ongoing investment in developing new solutions for people living with central nervous system (CNS) disorders.
Neuraxpharm operates with headquarters in Langenfeld (Düsseldorf) and Sant Joan Despí (Barcelona), with its manufacturing facility – Neuraxpharm Pharmaceuticals – based in the latter which focuses on the development and production of pharmaceutical products both for the Group and for national and international partners. Our HealthTech R&D centre serves as a global platform for excellence, accelerating research and development across neurology and psychiatry with a growing focus on multiple sclerosis as an area of high unmet medical need. Today, we have more than 25 new products in our pipeline, several of which are based on advanced technologies developed through strategic alliances with global partners.
In line with our international growth strategy, Neuraxpharm has established a presence in more than 20 European countries and continues to expand globally, with subsidiaries in Latin America, the Middle East, and Australia. Through our direct network and partnerships, we reach 98% of the European CNS market and deliver our products to patients in more than 50 countries worldwide.
In Spain, Neuraxpharm employs over 500 people across our manufacturing site, R&D centre, and corporate and commercial functions, contributing to a diverse and global workforce of approximately 1,100 skilled professionals.
This week’s visit from the Mayor highlighted the importance of the pharmaceutical industry in the Barcelona region, which is widely recognised for its robust ecosystem of pharmaceutical companies, manufacturing infrastructure and R&D expertise. It further underlined the value of continued collaboration between industry and local institutions in supporting scientific progress and economic development.